

Amendments to the Specification

Please amend the title at page 1 of the specification as follows:

~~DENDRITIC CELL INFILTRATIVITY ACTIVATING COMPOSITION AND
IMMUNE ACTIVATOR COMPOSITIONS FOR ACTIVATING THE INFILTRATION
ACTIVITY OF DENDRITIC CELLS, AND IMMUNOPOTENTIATING AGENTS~~

Please add the following new paragraph to page 1 of the specification after the title:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Stage application under 35 U.S.C. § 371 and claims benefit under 35 U.S.C. § 119(a) of International Application No. PCT/JP03/08720 having an International Filing Date of July 9, 2003.

Please replace the paragraph beginning at page 3, line 27 with the following amended paragraph:

The compositions of the present invention for activating the infiltration activity of dendritic cells comprise retinoid. The retinoids to be used in the compositions of the present invention for activating the infiltration activity of dendritic cells include, for example, retinoic acids, retinals, retinols, and retinyl fatty acid esters, as well as dehydroretinols, ~~dehydroretinols~~ ~~dehydroretinals~~, and dehydroretinyl fatty acid esters.

Please replace the paragraph beginning at page 6, line 34 with the following amended paragraph:

The methods of the present invention for activating the infiltration activity of dendritic cells comprise retinoid administration to mammals. The retinoids to be used in the methods of the present invention for activating the infiltration activity of dendritic cells include, for example, retinoic acids, retinals, retinols, retinyl fatty acid esters, dehydroretinols, ~~dehydroretinols~~ ~~dehydroretinals~~, and dehydroretinyl fatty acid esters.

Please replace the paragraph beginning at page 8, line 2 with the following amended paragraph:

The present invention's methods for potentiating immunity cells comprise retinoid administration to mammals. The retinoids to be used in the present invention's methods for potentiating immunity include, for example, retinoic acids, retinals, retinols, retinyl fatty acid esters, dehydroretinols, dehydroretinols dehydroretinals, and dehydroretinyl fatty acid esters.

Please replace the paragraph beginning at page 11, line 27 with the following amended paragraph:

As shown in Fig. 4, immature and mature dendritic cells that differentiated under normoxic conditions secreted the MMP-9 protein at higher levels than those that differentiated under hypoxic conditions. The active form of MMP-9 (labeled as “active MMP-9” in Fig. 4) was detected in only dendritic cells that differentiated under normoxic conditions. Then, immature and mature dendritic cells that differentiated under normoxic or hypoxic conditions were tested for the proteolytic activity of the MMP-9 protein secreted from the cells. As shown in Fig. 5, the gelatin zymograph shows that the dendritic cells that differentiated under normoxic conditions secreted pro-MMP-9 at higher levels than those that differentiated under hypoxic conditions. The active form of the MMP-9 protein (labeled as “active MMP-9” in Fig. 5) was only secreted in dendritic cells that differentiated under normoxic condition. These results show that the proteolytic activity is lower in dendritic cells that differentiated under hypoxic conditions than in those that differentiated under normoxic conditions.

Please add the Abstract on the attached page to the application.